Ophthalmic lifitegrast is used to treat the signs and symptoms of dry eye disease. Lifitegrast is in a class of medications called lymphocyte function-associated antigen-1 (LFA-1) antagonist. Lifitegrast works by reducing the swelling in the eye tissues
Lifitegrast is a small molecule integrin antagonist developed for ophthalmic therapy. Its core synthesis involves advanced organic coupling strategies targeting the alpha-4 beta-7 integrin. The compound features the molecular formula C28H36N6O5S and carries CAS number 1093789-37-3.
Contraindicated in patients with active ocular infections. Storage requires controlled room temperature away from moisture. Strict adherence to GMP guidelines is mandatory during API handling to ensure purity and stability.